D.E. Shaw & Co
AEON icon

D.E. Shaw & Co’s AEON Biopharma AEON Stock Holding History

D.E. Shaw & Co’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,444
Closed -$11.9M – 4388
2022
Q4 		$11.9M Buy
16,444
+5,396
+49% +$3.87M 0.01% 1300
2022
Q3 		$7.84M Hold
11,048
– – 0.01% 1583
2022
Q2 		$7.8M Buy
11,048
+3,248
+42% +$2.29M 0.01% 1642
2022
Q1 		$5.49M Buy
7,800
+4,947
+173% +$3.47M 0.01% 2204
2021
Q4 		$2M Buy
2,853
+1,240
+77% +$872K ﹤0.01% 3364
2021
Q3 		$1.13M Buy
1,613
+224
+16% +$156K ﹤0.01% 3508
2021
Q2 		$963K Buy
+1,389
New +$971K ﹤0.01% 3580

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

D.E. Shaw & Co's AEON Position: Q1 2023 in Review

D.E. Shaw & Co sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 16,444 shares — an estimated $11.9M sold.

D.E. Shaw & Co first reported a position in AEON in Q2 2021 and held it in 7 quarters. The position peaked at $11.9M in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • D.E. Shaw & Co reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 16,444 AEON Biopharma shares in Q1 2023, an estimated $11.9M.
  • D.E. Shaw & Co first reported a position in AEON Biopharma in Q2 2021 and held it in 7 quarters.
  • D.E. Shaw & Co's AEON Biopharma position peaked at $11.9M in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.